Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.31 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.31 |
| ▸ | ATR | Q13535 | 1/20 | 0.30 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.30 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24631040 | 1.00 | F2RL1 (0.35) | F2RL1DGAT1SLC5A1SLC5A2ATR | |
| SCHEMBL1957623 | 0.81 | F2RL1 (0.39) | F2RL1DGAT1KLKB1ALOX5APFEN1 | |
| SCHEMBL22864153 | 0.81 | DGAT1 (0.39) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL29593705 | 0.81 | DGAT1 (0.39) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL22864152 | 0.78 | F2RL1 (0.37) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL25852658 | 0.76 | F2RL1 (0.39) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL29594153 | 0.75 | F2RL1 (0.43) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL28724403 | 0.75 | F2RL1 (0.43) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL24631037 | 0.75 | F2RL1 (0.43) | F2RL1DGAT1ALOX5APFEN1 | |
| SCHEMBL1958899 | 0.73 | KDM1A (0.37) | F2RL1DGAT1ALOX5APFEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114340740-A | Beta adrenergic agonists and methods of use thereof | 库拉森疗法公司 | 2022-04-12 | — | — | CN | disclosed |